Table 1.

Clinical trials of PD-1 blockade combined with drugs targeting macrophages*.

Strategy	Cancer types	Clinical phase	Status/outcomes	Clinical identifier	Clinical Remark
Nivolumab + Cabiralizumab	PTCL	2	Active, not recruiting	NCT03927105	66.7% complete response rate at 4 months in 3 participants up to now
	Resectable BTC	2	Withdrawn	NCT03768531	No subject enrolled
Pembrolizumab + IMC-CS4	PAAD	1	Active, not recruiting	NCT03153410	No results posted
Pembrolizumab + ARRY-382	Advanced Solid Tumors	2	Terminated	NCT02880371	Halted due to insufficient efficacy
Pembrolizumab + PLX3397	Melanoma, NSCLC, HNSCC	1,2	Terminated	NCT02452424	Terminated early for insufficient evidence of clinical efficacy
PDR001 + BLZ945	Advanced Solid Tumors	1,2	Terminated	NCT02829723	No Results Posted
Nivolumab + BMS-813160	NSCLC, HCC	2	Recruiting	NCT04123379	No Results Posted
	Advanced PDAC	1,2	Recruiting	NCT03767582	Neoadjuvant and adjuvant trial
	PDAC	1,2	Recruiting	NCT03496662	Adverse events as anemia, nausea, fatigue, alopecia Increased objective response rate (ORR) when dose expansion
	PAAD	1,2	Active, not recruiting	NCT03184870	No Results Posted

* The data source from https://www.clinicaltrials.gov and the latest update date is March 9, 2023. Abbreviations, PTCL, Peripheral T Cell Lymphoma; BTC, Biliary Tract Cancer; NSCLC, Non-Small Cell Lung Cancer; PAAD, Pancreatic Cancer; HNSCC, Head and Neck Squamous Cell Carcinoma; HCC, Hepatocellular Carcinoma; PDAC, Pancreatic Ductal Adenocarcinoma; CRC, Colorectal Cancer; ICC, Intrahepatic Cholangiocarcinoma; HM, Hematologic Malignancies; MCC, Merkel-cell Carcinoma; SQC, Squamous Cell Carcinoma; MM, Multiple Myeloma; BRCA, Breast Carcinoma; HPV, Human Papillomavirus; HNC, Head and Neck Cancer; GAC, Gastric Adenocarcinoma; AML, Acute Myeloid Leukemia; MDS, Myelodysplastic Syndromes; NHL, Non-Hodgkin Lymphoma; MSS-mCRC, Microsatellite Stable Metastatic Colorectal Cancer; OCA, Ovarian Cancer; LMS, Leiomyosarcoma; CHN, Carcinoma of the Head and Neck; DLBCL, Diffuse Large B-Cell Lymphoma; FL, Follicular Lymphoma; MZL, Marginal Zone Lymphoma; MCL, Mantle Cell Lymphoma; CLL, Chronic Lymphocytic Lymphoma; BCL, B-Cell Lymphoma; EOC, Epithelial Ovarian Cancer; TNBC, Triple Negative Breast Cancer.